Add this topic to your myFT Digest for news straight to your inbox
Deep pool of retail and institutional investors has helped Stockholm defy continent’s capital markets gloom
Plus, Goldman Sachs goes back to basics and the Swedish powerhouse behind EQT
Revived plan follows years of internal discord over whether private equity firm should list
Market sentiment is bound to be more fragile than it was only last week
Transition, as in Rubrik’s case, complicates the financial picture and could weigh on valuations
Private equity firm seeks valuation of up to €15bn after pressing ahead with float despite geopolitical turmoil
SoftBank-backed fintech aims to offer current accounts to existing customers by end of 2024
Recent flotations of Galderma and Douglas underscore that fund managers are still being selective
European private equity group set to renew push for high-profile listing
Introducing a UK market mixed motoring metaphor metric
Private equity pioneer looks to exit more investments as it pushes for goal of $1tn in assets
The plan to run periodic auctions that concentrate activity over a short time window is sensible
Executives at Vitol, Trafigura and Mercuria say banks and export credit agencies have never been so keen to lend to them
CEO of private markets platform says many companies listed on Aim ‘would prefer not to be’
Puig has been buying up brands and its diversification into cosmetics is paying off
Family business behind Charlotte Tilbury and Paco Rabanne plans to list in Madrid and other Spanish stock exchanges
Peel Hunt chief says dearth of IPOs is ‘starting to bite quite hard’
Group valued at $2.4bn, whose backers include SoftBank, says it has begun work for an eventual float
Data shows a ‘sustained slowdown’ has persisted in the first quarter of 2024 as a lack of exit options weighs on fundraising efforts
Ireland-based group plans to shift its primary listing from London to New York later this year
Fast-fashion group is seeking Chinese approval for IPO in New York or London
Monetising messaging apps is not easy, and listing changes the power structure and forces greater disclosure
Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity
Swiss company’s initial public offering would have been China’s largest in years
Heavy trading in company behind Truth Social fuels talk of a new cycle of ‘meme stock mania’
International Edition